Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER vs ISOLYTE E IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sodium lactate is an alkalinizing agent that is metabolized to bicarbonate in the liver, increasing plasma bicarbonate concentration and buffering hydrogen ions, thereby correcting metabolic acidosis. The lactate ion is converted to pyruvate and then to glucose or oxidized via the Krebs cycle, yielding bicarbonate.
ISOLYTE E is an intravenous electrolyte replacement solution that provides water, electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, and gluconate), and bicarbonate precursors to correct fluid and electrolyte imbalances. The acetate and gluconate ions are metabolized to bicarbonate in the liver, providing an alkaline buffer.
Treatment of mild to moderate metabolic acidosis,Correction of acid-base imbalance in conditions such as diabetic ketoacidosis (as an adjunct),Fluid resuscitation in hypovolemic states when alkalinization is desired (off-label)
Maintenance of fluid and electrolyte balance in patients unable to take oral intake,Correction of metabolic acidosis when bicarbonate is contraindicated or not available,Replacement of electrolytes in hypokalemia, hyponatremia, hypomagnesemia, and hypocalcemia
Intravenous infusion; initial dose 300-500 m L (50-83 mmol) administered over 1-2 hours; subsequent doses based on serum bicarbonate and clinical response. Maximum infusion rate: 300 m L/h.
Intravenous infusion; rate and volume determined by individual patient requirements for fluid and electrolyte replacement. Typical adult dose: 500-1000 m L as a single infusion, administered at a rate of 5-10 m L/min.
Lactate has a plasma half-life of approximately 5-10 minutes in healthy individuals. In patients with hepatic impairment or shock, half-life may be prolonged to 1-2 hours due to reduced metabolism.
Not applicable as a single agent; components have variable half-lives (e.g., sodium and chloride distribute rapidly with an elimination half-life of 2-4 hours depending on renal function). In renal impairment, half-life may be prolonged.
Lactate is metabolized primarily in the liver via lactate dehydrogenase to pyruvate, then enters the gluconeogenesis pathway or the Krebs cycle for oxidation to carbon dioxide and water, generating bicarbonate. Metabolism is dependent on hepatic function.
Acetate and gluconate are metabolized in the liver via the tricarboxylic acid cycle to bicarbonate; electrolytes are distributed in body fluids and excreted renally.
Sodium lactate is metabolized to bicarbonate primarily in the liver (60-70%) and kidneys (30-40%). Excretion of unmetabolized lactate is minimal (<5%) via urine. Biliary/fecal excretion negligible.
Renal: >95% of administered electrolytes and water are excreted unchanged by the kidneys, primarily as urine. Biliary/fecal: <5% eliminated via feces, mainly unabsorbed components.
Lactate is not significantly protein-bound (<1%). It is freely filtered and metabolized.
Minimal to none: electrolytes like sodium, potassium, chloride, and bicarbonate are not protein-bound (<1%). Magnesium and calcium may have 30-50% binding to albumin, but overall negligible in solution.
Volume of distribution for lactate is approximately 0.3-0.5 L/kg, reflecting distribution into total body water and rapid cellular uptake.
Distributes primarily into extracellular fluid (ECF) with Vd approximately 0.2 L/kg for sodium and chloride; calcium and magnesium distribute into a larger volume (0.5-0.6 L/kg) due to intracellular uptake.
Only relevant route is intravenous; oral lactate is rapidly metabolized in the liver (first-pass effect), but no IV bioavailability data exists; effectively 100% for IV administration.
Intravenous: 100% (complete systemic availability). Not administered orally or by other routes for systemic effect.
GFR 30-50 m L/min: caution, monitor for volume overload and electrolyte disturbances; GFR <30 m L/min: avoid due to risk of sodium overload and metabolic alkalosis. No specific dose reduction; use with close monitoring.
Contraindicated in patients with severe renal impairment (GFR < 30 m L/min) due to risk of hyperkalemia. For GFR 30-50 m L/min, reduce infusion rate by 50% and monitor serum potassium closely. No adjustment needed for GFR > 50 m L/min.
Child-Pugh A-B: no adjustment; Child-Pugh C: caution due to impaired lactate metabolism; monitor for acidosis/alkalosis.
Child-Pugh Class A: no adjustment. Class B: reduce infusion rate by 25% and monitor serum potassium. Class C: use with caution; consider alternative solutions due to risk of electrolyte imbalance.
Neonates and infants: 2-5 m L/kg (0.33-0.83 mmol/kg) intravenously over 1-2 hours; repeated as needed based on acid-base status. Children: 5-10 m L/kg (0.83-1.66 mmol/kg) IV over 1-2 hours. Maximum infusion rate: 5 m L/kg/h.
Weight-based dosing: 20-30 m L/kg as a single intravenous infusion, administered at a rate not exceeding 5 m L/kg/hour. Maximum total volume: 1000 m L. Adjust based on clinical status and serum electrolytes.
Start at lower end of adult dose (300 m L) due to decreased renal function and risk of fluid overload; monitor electrolytes and volume status closely.
Elderly patients may require reduced infusion rates (2-5 m L/min) due to decreased renal function and higher risk of fluid overload. Monitor serum potassium and renal function closely.
None
None
Use with caution in patients with impaired liver function, as conversion to bicarbonate may be reduced,Risk of metabolic alkalosis with excessive administration,Should not be used in severe metabolic acidosis (p H < 7.1) or lactic acidosis,Monitor serum electrolytes, p H, and fluid status during administration,Contains sodium; use with caution in patients with congestive heart failure, edema, or renal impairment
Monitor serum electrolytes, fluid balance, and renal function regularly. Use with caution in patients with heart failure, renal impairment, or conditions predisposing to hypervolemia. Avoid rapid infusion; extravasation may cause tissue damage. Contains aluminum, which may accumulate in renal impairment.
Severe metabolic acidosis (p H < 7.1),Lactic acidosis,Alkalosis,Hypernatremia,Fluid overload states,Severe hepatic failure (inability to convert lactate to bicarbonate),Known hypersensitivity to sodium lactate or any component of the formulation
Hyperkalemia, hypernatremia, hypercalcemia, hypermagnesemia, severe metabolic alkalosis, severe renal failure with oliguria or anuria, and patients with a known hypersensitivity to any component.
No significant food-drug interactions are known. However, patients on sodium-restricted diets should be informed of the sodium content of this solution.
No direct food interactions; however, patients should avoid high-potassium foods (e.g., bananas, oranges, tomatoes) if hyperkalemia is a concern. Monitor dietary sodium and fluid intake as per clinical status.
Sodium lactate, as a component of lactated Ringer's solution, is generally considered safe during pregnancy. No teratogenic effects have been reported in humans. It is used intravenously for fluid and electrolyte replacement. The risk to the fetus is minimal when used according to standard clinical practice across all trimesters.
ISOLYTE E in plastic container is a balanced electrolyte solution without known teratogenic risk. No fetal harm has been documented in any trimester; however, excessive or rapid administration may cause maternal fluid and electrolyte disturbances that can indirectly affect the fetus. Use with caution in the setting of impaired uteroplacental perfusion.
Sodium lactate is a normal component of breast milk and is not expected to cause adverse effects. The M/P ratio is not specifically defined but is likely similar to plasma levels. Use during breastfeeding is considered safe.
ISOLYTE E is compatible with breastfeeding. Electrolytes are normally present in breast milk; exogenous administration does not significantly alter infant exposure. M/P ratio not applicable as drug is not a xenobiotic.
Standard dosing for fluid and electrolyte replacement is generally appropriate during pregnancy. No specific dose adjustments are typically required, but careful monitoring of volume status and electrolytes is recommended due to potential pregnancy-related changes in renal function and hemodynamics.
No dose adjustment is required for pregnancy. However, pregnant patients may have increased plasma volume and altered renal function; infusion rates should be individualized based on clinical status and serum electrolyte monitoring. Rapid correction of electrolyte imbalances should be avoided to prevent fetal osmotic shifts.
Sodium lactate 0.167 Molar is an isotonic crystalloid solution primarily used as a source of bicarbonate precursors in metabolic acidosis. Monitor serum lactate levels to distinguish iatrogenic hyperlactatemia from lactic acidosis. Avoid in patients with severe metabolic alkalosis or hypernatremia. Use with caution in hepatic impairment due to impaired lactate clearance. In cardiac arrest, consider use only if indicated by arterial blood gas; routine use is not recommended.
ISOLYTE E is a balanced electrolyte solution with 5% dextrose, used for maintenance fluid therapy. Monitor serum potassium closely in renal impairment; contains 20 m Eq/L potassium. Caution in patients with hyperkalemia, renal failure, or metabolic alkalosis. Do not administer simultaneously with blood products due to risk of hemolysis. Observe for signs of fluid overload in patients with heart failure.
This intravenous solution provides electrolytes and fluid to help correct body acid imbalance.,Tell your healthcare provider if you have a history of liver disease, kidney problems, or are on a low-sodium diet.,Report any symptoms such as muscle twitching, confusion, or irregular heartbeat during infusion.,You may experience temporary discomfort or swelling at the infusion site.
This solution is used to replace fluids and electrolytes and provide calories. Tell your doctor if you have kidney problems, heart disease, or are on a low-potassium diet. Report any swelling, shortness of breath, or irregular heartbeat. Do not take over-the-counter potassium supplements without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER vs ISOLYTE E IN PLASTIC CONTAINER, answered by our medical review team.
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER is a Electrolyte Solution that works by Sodium lactate is an alkalinizing agent that is metabolized to bicarbonate in the liver, increasing plasma bicarbonate concentration and buffering hydrogen ions, thereby correcting metabolic acidosis. The lactate ion is converted to pyruvate and then to glucose or oxidized via the Krebs cycle, yielding bicarbonate.. ISOLYTE E IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by ISOLYTE E is an intravenous electrolyte replacement solution that provides water, electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, and gluconate), and bicarbonate precursors to correct fluid and electrolyte imbalances. The acetate and gluconate ions are metabolized to bicarbonate in the liver, providing an alkaline buffer.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER and ISOLYTE E IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER is: Intravenous infusion; initial dose 300-500 m L (50-83 mmol) administered over 1-2 hours; subsequent doses based on serum bicarbonate and clinical response. Maximum infusion rate: 300 m L/h.. The standard adult dose of ISOLYTE E IN PLASTIC CONTAINER is: Intravenous infusion; rate and volume determined by individual patient requirements for fluid and electrolyte replacement. Typical adult dose: 500-1000 m L as a single infusion, administered at a rate of 5-10 m L/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER and ISOLYTE E IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER is classified as Category C. Sodium lactate, as a component of lactated Ringer's solution, is generally considered safe during pregnancy. No teratogenic effects have been reported in humans. It is used intrave. ISOLYTE E IN PLASTIC CONTAINER is classified as Category C. ISOLYTE E in plastic container is a balanced electrolyte solution without known teratogenic risk. No fetal harm has been documented in any trimester; however, excessive or rapid ad. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.